Rabbit Polyclonal SETD7 Antibody

The SETD7 antibody is a crucial tool for studying the SET domain-containing protein 7 (SETD7), also known as KMT7 or SET7/9. a member of the histone methyltransferase family. SETD7 specifically catalyzes the monomethylation of histone H3 at lysine 4 (H3K4me1), an epigenetic modification associated with transcriptional activation. Beyond histones, SETD7 methylates non-histone substrates like p53. ERα, STAT3. and DNMT1. regulating diverse cellular processes including cell cycle progression, differentiation, inflammation, and cancer progression. Antibodies targeting SETD7 enable researchers to detect its expression levels, subcellular localization, and interactions in various experimental models, using techniques such as Western blotting (WB), immunohistochemistry (IHC), immunofluorescence (IF), and immunoprecipitation (IP). These antibodies are vital for exploring SETD7's dual roles in diseases; it acts as both a tumor suppressor and oncogene in different cancers, influences neurodegenerative pathways, and modulates metabolic disorders. Commercial SETD7 antibodies are available from multiple suppliers (e.g., Abcam, Cell Signaling Technology, Santa Cruz Biotechnology) and are typically validated for specificity using knockout controls. Structural studies reveal SETD7 contains a catalytic SET domain at the C-terminus and regulatory regions at the N-terminus, which may be targeted by isoform-specific antibodies. Ongoing research leverages these antibodies to dissect SETD7's context-dependent functions and therapeutic potential.